TARGET-GASTRO is an observational research study to conduct a comprehensive review of outcomes for patients with the chronic gastrointestinal (GI) diseases: eosinophilic gastrointestinal disease (EGID), ulcerative colitis (UC) or Crohn's disease (CD).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Disease Cohort
Inclusion Criteria:
* Adult\* patients at the time of enrollment with a diagnosis or major symptom of EGIDs, UC, or CD by ICD-10 code in the EHR interface
Exclusion Criteria:
* Death
* Manual removal (sponsor or site request)
* No EHR interface encounter \> 3 years.
Engaged Cohort
Inclusion Criteria:
* Adult\* patients diagnosed and managed for these conditions invited to participate
* Ability to provide written informed consent
Exclusion Criteria:
* Patient expressed desire to withdraw consent to complete PROs
* Failure to complete PROs within 24 weeks of initial invitation
* Greater than 24 months lapse of survey completion after baseline surveys completed
* Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort.
Primary outcome measure(s)
To characterize the natural history of disease in patients with GI disease from various etiologies — 20 Years
To assess safety and effectiveness of treatments — 20 Years
Trial sites (1)
Facility
City
Region
Status
Atrium Health/Wake Forest University School of Medicine
Winston-Salem
North Carolina
More Target PharmaSolutions, Inc. trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.